Secondary negative symptoms — A review of mechanisms, assessment and treatment

Addington, 2014, Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis, Schizophr. Res., 153, 64, 10.1016/j.schres.2013.12.014 Akhondzadeh, 2008, Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 32, 1879, 10.1016/j.pnpbp.2008.08.020 Armijo, 2013, Efficacy of community treatments for schizophrenia and other psychotic disorders: a literature review, Front. Psychiatry, 4, 116, 10.3389/fpsyt.2013.00116 Arrondo, 2015, Reduction in ventral striatal activity when anticipating a reward in depression and schizophrenia: a replicated cross-diagnostic finding, Front. Psychol., 6, 1280, 10.3389/fpsyg.2015.01280 Artaloytia, 2006, Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers, Am. J. Psychiatry, 163, 488, 10.1176/appi.ajp.163.3.488 Barch, 2010, Goal representations and motivational drive in schizophrenia: the role of prefrontal–striatal interactions, Schizophr. Bull., 36, 919, 10.1093/schbul/sbq068 Barch, 2015, Mechanisms underlying motivational deficits in psychopathology: similarities and differences in depression and schizophrenia, Curr. Top. Behav. Neurosci., 10.1007/7854_2015_376 Barnes, 1989, The nature and prevalence of depression in chronic schizophrenic in-patients, Br. J. Psychiatry J. Ment. Sci., 154, 486, 10.1192/bjp.154.4.486 Barton, 1959 Baynes, 2000, Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment, Schizophr. Res., 45, 47, 10.1016/S0920-9964(99)00205-4 Bermanzohn, 1992, Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia, Compr. Psychiatry, 33, 221, 10.1016/0010-440X(92)90045-R Berridge, 2003, Parsing reward, Trends Neurosci., 26, 507, 10.1016/S0166-2236(03)00233-9 Blanchard, 2006, The structure of negative symptoms within schizophrenia: implications for assessment, Schizophr. Bull., 32, 238, 10.1093/schbul/sbj013 Bobes, 2010, Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study, J. Clin. Psychiatry, 71, 280, 10.4088/JCP.08m04250yel Brébion, 2000, Depression, psychomotor retardation, negative symptoms, and memory in schizophrenia, Neuropsychiatry Neuropsychol. Behav. Neurol., 13, 177 Buchanan, 2007, Persistent negative symptoms in schizophrenia: an overview, Schizophr. Bull., 33, 1013, 10.1093/schbul/sbl057 Buchanan, 2010, The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements, Schizophr. Bull., 36, 71, 10.1093/schbul/sbp116 Buckley, 2009, Psychiatric comorbidities and schizophrenia, Schizophr. Bull., 35, 383, 10.1093/schbul/sbn135 Butler, 2006, The empirical status of cognitive-behavioral therapy: a review of meta-analyses, Clin. Psychol. Rev., 26, 17, 10.1016/j.cpr.2005.07.003 Carpenter, 1985, Treatment of negative symptoms, Schizophr. Bull., 11, 440, 10.1093/schbul/11.3.440 Carpenter, 1988, Deficit and nondeficit forms of schizophrenia: the concept, Am. J. Psychiatry, 145, 578, 10.1176/ajp.145.5.578 Chang, 2015, Rate and risk factors of depressive symptoms in Chinese patients presenting with first-episode non-affective psychosis in Hong Kong, Schizophr. Res., 168, 99, 10.1016/j.schres.2015.07.040 Chen, 2013, The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial, BMC Psychiatry, 13, 320, 10.1186/1471-244X-13-320 Czobor, 1996, Positive and negative symptoms: is their change related?, Schizophr. Bull., 22, 577, 10.1093/schbul/22.4.577 Dichter, 2012, Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings, J. Neurodev. Disord., 4, 19, 10.1186/1866-1955-4-19 Dichter, 2012, Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes, J. Affect. Disord., 136, 1126, 10.1016/j.jad.2011.09.048 Dollfus, 1995, Depressive symptoms and negative symptoms during schizophrenia, 23 Duinkerke, 1993, Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial, Br. J. Psychiatry J. Ment. Sci., 163, 451, 10.1192/bjp.163.4.451 Elis, 2013, Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions, Clin. Psychol. Rev., 33, 914, 10.1016/j.cpr.2013.07.001 Esslinger, 2012, Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients, Schizophr. Res., 140, 114, 10.1016/j.schres.2012.06.025 Fervaha, 2015, Antipsychotics and amotivation, Neuropsychopharmacology, 40, 1539, 10.1038/npp.2015.3 Fusar-Poli, 2015, Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials, Schizophr. Bull., 41, 892, 10.1093/schbul/sbu170 Galderisi, 2013, Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome, Schizophr. Res., 147, 157, 10.1016/j.schres.2013.03.020 Galderisi, 2014, The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia, World Psychiatry Off. J. World Psychiatr. Assoc. WPA, 13, 275 Garfield, 2014, Anhedonia in substance use disorders: a systematic review of its nature, course and clinical correlates, Aust. N. Z. J. Psychiatry, 48, 36, 10.1177/0004867413508455 Gawin, 1986, Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations, Arch. Gen. Psychiatry, 43, 107, 10.1001/archpsyc.1986.01800020013003 Gerlach, 1993, The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity, Acta Psychiatr. Scand., 87, 244, 10.1111/j.1600-0447.1993.tb03366.x Greenberg, 2015, Moderation of the relationship between reward expectancy and prediction error-related ventral striatal reactivity by anhedonia in unmedicated major depressive disorder: findings from the EMBARC study, Am. J. Psychiatry, 172, 881, 10.1176/appi.ajp.2015.14050594 Groenewold, 2013, Emotional valence modulates brain functional abnormalities in depression: evidence from a meta-analysis of fMRI studies, Neurosci. Biobehav. Rev., 37, 152, 10.1016/j.neubiorev.2012.11.015 Häfner, 1999, Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia, Acta Psychiatr. Scand., 100, 105, 10.1111/j.1600-0447.1999.tb10831.x Hasan, 2012, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance, World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry, 13, 318, 10.3109/15622975.2012.696143 Hasan, 2013, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects, World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry, 14, 2, 10.3109/15622975.2012.739708 Hasan, 2015, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation, World J. Biol. Psychiatry, 16, 142, 10.3109/15622975.2015.1009163 Heinz, 2010, Dopaminergic dysfunction in schizophrenia: salience attribution revisited, Schizophr. Bull., 36, 472, 10.1093/schbul/sbq031 Heinz, 1998, Psychomotor slowing, negative symptoms and dopamine receptor availability—an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients, Schizophr. Res., 31, 19, 10.1016/S0920-9964(98)00003-6 Howes, 2009, The dopamine hypothesis of schizophrenia: version III—the final common pathway, Schizophr. Bull., 35, 549, 10.1093/schbul/sbp006 Ikemoto, 2015, Basal ganglia circuit loops, dopamine and motivation: a review and enquiry, Behav. Brain Res., 290, 17, 10.1016/j.bbr.2015.04.018 Insel, 2014, Antipsychotic dose modulates behavioral and neural responses to feedback during reinforcement learning in schizophrenia, Cogn. Affect. Behav. Neurosci., 14, 189, 10.3758/s13415-014-0261-3 Jäger, 2008, Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response, Psychiatry Res., 158, 297, 10.1016/j.psychres.2007.01.002 Johnson, 1994, Relationship between neuroleptic dose and positive and negative symptoms, Psychol. Rep., 74, 481, 10.2466/pr0.1994.74.2.481 Juckel, 2006, Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics, Psychopharmacology Berl, 187, 222, 10.1007/s00213-006-0405-4 Juckel, 2006, Dysfunction of ventral striatal reward prediction in schizophrenia, NeuroImage, 29, 409, 10.1016/j.neuroimage.2005.07.051 Kalechstein, 2002, Apathy syndrome in cocaine dependence, Psychiatry Res., 109, 97, 10.1016/S0165-1781(01)00354-7 Kane, 1988, Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine, Arch. Gen. Psychiatry, 45, 789, 10.1001/archpsyc.1988.01800330013001 Kelley, 1999, Empirical validation of primary negative symptoms: independence from effects of medication and psychosis, Am. J. Psychiatry, 156, 406, 10.1176/ajp.156.3.406 Kibel, 1993, The composition of the negative syndrome of chronic schizophrenia, Br. J. Psychiatry J. Ment. Sci., 162, 744, 10.1192/bjp.162.6.744 Kirkpatrick, 2014, Developing concepts in negative symptoms: primary vs secondary and apathy vs expression, J. Clin. Psychiatry, 75, 3, 10.4088/JCP.13049su1c.01 Kirkpatrick, 2008, Deficit schizophrenia: an update, World Psychiatry, 7, 143, 10.1002/j.2051-5545.2008.tb00181.x Kirkpatrick, 1989, The schedule for the deficit syndrome: an instrument for research in schizophrenia, Psychiatry Res., 30, 119, 10.1016/0165-1781(89)90153-4 Kirkpatrick, 2001, A separate disease within the syndrome of schizophrenia, Arch. Gen. Psychiatry, 58, 165, 10.1001/archpsyc.58.2.165 Kirsch, 2007, The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients, Pharmacopsychiatry, 40, 196, 10.1055/s-2007-984463 Kirschner, 2015, Ventral striatal hypoactivation is associated with apathy but not diminished expression in patients with schizophrenia, Jpn. J. Psychiatry Neurol., 40, 140383 Knights, 1981, “Revealed” depression and drug treatment for schizophrenia, Arch. Gen. Psychiatry, 38, 806, 10.1001/archpsyc.1981.01780320086010 Koreen, 1993, Depression in first-episode schizophrenia, Am. J. Psychiatry, 150, 1643, 10.1176/ajp.150.11.1643 Kreyenbuhl, 2010, The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009, Schizophr. Bull., 36, 94, 10.1093/schbul/sbp130 Kring, 2014, The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol., 24, 725, 10.1016/j.euroneuro.2013.06.007 Kuck, 1992, Negative symptomatology in schizophrenic outpatients, J. Nerv. Ment. Dis., 180, 510, 10.1097/00005053-199208000-00006 Kuipers, 2014, Management of psychosis and schizophrenia in adults: summary of updated NICE guidance, BMJ, 348, g1173, 10.1136/bmj.g1173 Kulhara, 1989, Negative and depressive symptoms in schizophrenia, Br. J. Psychiatry, 154, 207, 10.1192/bjp.154.2.207 Kurtz, 2015, Comprehensive treatments for social cognitive deficits in schizophrenia: a critical review and effect-size analysis of controlled studies, Clin. Psychol. Rev. Lako, 2012, A systematic review of instruments to measure depressive symptoms in patients with schizophrenia, J. Affect. Disord., 140, 38, 10.1016/j.jad.2011.10.014 Lançon, 2000, Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS), J. Affect. Disord., 58, 107, 10.1016/S0165-0327(99)00075-0 Large, 2014, Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use, Aust. N. Z. J. Psychiatry, 48, 418, 10.1177/0004867414525838 Leucht, 2009, How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials, Mol. Psychiatry, 14, 429, 10.1038/sj.mp.4002136 Leucht, 2009, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, Lancet, 373, 31, 10.1016/S0140-6736(08)61764-X Leventhal, 2008, Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder, Am. J. Addict., 17, 218, 10.1080/10550490802019774 Lewander, 1994, Neuroleptics and the neuroleptic-induced deficit syndrome, Acta Psychiatr. Scand. Suppl., 380, 8, 10.1111/j.1600-0447.1994.tb05825.x Liemburg, 2012, Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol., 22, 387, 10.1016/j.euroneuro.2011.12.008 Liemburg, 2013, Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts, J. Psychiatr. Res., 47, 718, 10.1016/j.jpsychires.2013.01.024 Lindenmayer, 1991, Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms, Compr. Psychiatry, 32, 528, 10.1016/0010-440X(91)90032-8 Lyne, 2015, Negative symptom domain prevalence across diagnostic boundaries: the relevance of diagnostic shifts, Psychiatry Res., 10.1016/j.psychres.2015.05.086 Marder, 1994, Risperidone in the treatment of schizophrenia, Am. J. Psychiatry, 151, 825, 10.1176/ajp.151.6.825 Marder, 1997, The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials, J. Clin. Psychiatry, 58, 538, 10.4088/JCP.v58n1205 Mas, 2013, Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial, Hum. Psychopharmacol. Clin. Exp., 28, 586, 10.1002/hup.2350 McGlashan, 1976, Postpsychotic depression in schizophrenia, Arch. Gen. Psychiatry, 33, 231, 10.1001/archpsyc.1976.01770020065011 McGlashan, 1976, An investigation of the postpsychotic depressive syndrome, Am. J. Psychiatry, 133, 14, 10.1176/ajp.133.1.14 Milev, 2005, Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up, Am. J. Psychiatry, 162, 495, 10.1176/appi.ajp.162.3.495 Miller, 2004, Atypical antipsychotics: sleep, sedation, and efficacy, Prim. Care Companion J. Clin. Psychiatry, 6, 3 Miller, 1994, Effect of antipsychotic withdrawal on negative symptoms in schizophrenia, Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol., 11, 11, 10.1038/npp.1994.31 Miller, 1994, Clozapine's effect on negative symptoms in treatment-refractory schizophrenics, Compr. Psychiatry, 35, 8, 10.1016/0010-440X(94)90164-3 Möller, 2005, Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues, World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry, 6, 247, 10.1080/15622970500316674 Möller, 2005, Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data, Eur. Arch. Psychiatry Clin. Neurosci., 255, 83, 10.1007/s00406-005-0580-z Möller, 2005, Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?, Eur. Arch. Psychiatry Clin. Neurosci., 255, 190, 10.1007/s00406-005-0587-5 Mucci, 2015, Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback, Psychol. Med., 1–14 Mueser, 2013, Psychosocial treatments for schizophrenia, Annu. Rev. Clin. Psychol., 9, 465, 10.1146/annurev-clinpsy-050212-185620 Mulholland, 2000, The symptom of depression in schizophrenia and its management, Adv. Psychiatr. Treat., 6, 169, 10.1192/apt.6.3.169 Murray, 2008, Substantia nigra/ventral tegmental reward prediction error disruption in psychosis, Mol. Psychiatry, 13, 267, 10.1038/sj.mp.4002058 Nielsen, 2012, Alterations of the brain reward system in antipsychotic naïve schizophrenia patients, 71, 898 Nordentoft, 1996, CCPP—Copenhagen Community Psychiatric Project. Implementation of community mental health centres in Copenhagen: effects of service utilization, social integration, quality of life and positive and negative symptoms, Soc. Psychiatry Psychiatr. Epidemiol., 31, 336, 10.1007/BF00783422 Norman, 1991, Dysphoric mood and symptomatology in schizophrenia, Psychol. Med., 21, 897, 10.1017/S0033291700029883 Oshima, 2003, Institutionalisation and schizophrenia in Japan: social environments and negative symptoms: nationwide survey of in-patients, Br. J. Psychiatry J. Ment. Sci., 183, 50, 10.1192/bjp.183.1.50 Oshima, 2005, Effects of environmental deprivation on negative symptoms of schizophrenia: a nationwide survey in Japan's psychiatric hospitals, Psychiatry Res., 136, 163, 10.1016/j.psychres.2005.06.001 Pani, 2002, The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia, Mol. Psychiatry, 7, 247, 10.1038/sj.mp.4001040 Park, 2012, No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial, Int. Clin. Psychopharmacol., 27, 114, 10.1097/YIC.0b013e3283502773 Peralta, 2000, Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment, Am. J. Psychiatry, 157, 1461, 10.1176/appi.ajp.157.9.1461 Pickar, 1992, Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine, Arch. Gen. Psychiatry, 49, 345, 10.1001/archpsyc.1992.01820050009001 Prosser, 1987, Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics, J. Nerv. Ment. Dis., 175, 100, 10.1097/00005053-198702000-00006 Radua, 2015, Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis, JAMA Psychiatry, 1243, 10.1001/jamapsychiatry.2015.2196 Ramaekers, 1999, Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic, J. Clin. Psychopharmacol., 19, 209, 10.1097/00004714-199906000-00003 Rifkin, 1975, Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder, Arch. Gen. Psychiatry, 32, 672, 10.1001/archpsyc.1975.01760230138011 Roiser, 2013, Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis, Schizophr. Bull., 39, 1328, 10.1093/schbul/sbs147 Roth, 1970, The seemingly ubiquitous depression following acute schizophrenic episodes, a neglected area of clinical discussion, Am. J. Psychiatry, 127, 51, 10.1176/ajp.127.1.51 Rovai, 2013, Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse, Riv. Psichiatr., 48, 1 Rummel, 2005, Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials, Schizophr. Res., 80, 85, 10.1016/j.schres.2005.07.035 Sands, 1999, Depression during the longitudinal course of schizophrenia, Schizophr. Bull., 25, 157, 10.1093/oxfordjournals.schbul.a033362 Sanger, 1999, Olanzapine versus haloperidol treatment in first-episode psychosis, Am. J. Psychiatry, 156, 79, 10.1176/ajp.156.1.79 Schlagenhauf, 2008, Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine, Psychopharmacology Berl, 196, 673, 10.1007/s00213-007-1016-4 Simon, 2010, Neural correlates of reward processing in schizophrenia—relationship to apathy and depression, Schizophr. Res., 118, 154, 10.1016/j.schres.2009.11.007 Simpson, 1970, A rating scale for extrapyramidal side effects, Acta Psychiatr. Scand. Suppl., 212, 11, 10.1111/j.1600-0447.1970.tb02066.x Singh, 2010, Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis, Br. J. Psychiatry J. Ment. Sci., 197, 174, 10.1192/bjp.bp.109.067710 Siris, 2000, Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents, Am. J. Psychiatry, 157, 1379, 10.1176/appi.ajp.157.9.1379 Siris, 1988, Postpsychotic depression and negative symptoms: an investigation of syndromal overlap, Am. J. Psychiatry, 145, 1532, 10.1176/ajp.145.12.1532 Siris, 2001, Depression in schizophrenia: recognition and management in the USA, Schizophr. Res., 47, 185, 10.1016/S0920-9964(00)00135-3 Spina, 1994, Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients, Int. Clin. Psychopharmacol., 9, 281, 10.1097/00004850-199400940-00007 Steel, 2015, A randomised controlled trial of positive memory training for the treatment of depression within schizophrenia, BMC Psychiatry, 15, 85, 10.1186/s12888-015-0453-6 Strauss, 2010, Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study, Schizophr. Bull., 36, 788, 10.1093/schbul/sbn167 Strauss, 2013, Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome, J. Psychiatr. Res., 47, 783, 10.1016/j.jpsychires.2013.01.015 Strauss, 2014, A review of reward processing and motivational impairment in schizophrenia, Schizophr. Bull., 40, S107, 10.1093/schbul/sbt197 Stringaris, 2015, The brain's response to reward anticipation and depression in adolescence: dimensionality, specificity, and longitudinal predictions in a community-based sample, Am. J. Psychiatry, 10.1176/appi.ajp.2015.14101298 Szeszko, 2008, Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia, Neuropsychopharmacology, 33, 976, 10.1038/sj.npp.1301480 Takeuchi, 2013, Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study, Schizophr. Bull., 39, 993, 10.1093/schbul/sbt090 Tandon, 1993, Positive and negative symptoms covary during clozapine treatment in schizophrenia, J. Psychiatr. Res., 27, 341, 10.1016/0022-3956(93)90060-F Tandon, 1993, Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication, Biol. Psychiatry, 34, 495, 10.1016/0006-3223(93)90242-6 Tandon, 2000, Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome, Schizophr. Res., 45, 191, 10.1016/S0920-9964(99)00163-2 Tollefson, 1997, Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial, Am. J. Psychiatry, 154, 457, 10.1176/ajp.154.4.457 Tollefson, 1998, Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol, Arch. Gen. Psychiatry, 55, 250, 10.1001/archpsyc.55.3.250 Tugg, 1997, Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects, Schizophr. Res., 25, 71, 10.1016/S0920-9964(97)00009-1 Wassink, 1999, Prevalence of depressive symptoms early in the course of schizophrenia, Am. J. Psychiatry, 156, 315, 10.1176/ajp.156.2.315 Whitehead, 2002, Antidepressants for people with both schizophrenia and depression, Cochrane Database Syst. Rev., 10.1002/14651858.CD002305 Whitehead, 2003, Antidepressants for the treatment of depression in people with schizophrenia: a systematic review, Psychol. Med., 33, 589, 10.1017/S0033291703007645 Whitton, 2015, Reward processing dysfunction in major depression, bipolar disorder and schizophrenia, Curr. Opin. Psychiatry, 28, 7, 10.1097/YCO.0000000000000122 Wing, 1970 Wolf, 2014, Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures, Schizophr. Bull., 10.1093/schbul/sbu026 Wolkin, 1992, Negative symptoms and hypofrontality in chronic schizophrenia, Arch. Gen. Psychiatry, 49, 959, 10.1001/archpsyc.1992.01820120047007 Wotruba, 2014, Symptom dimensions are associated with reward processing in unmedicated persons at risk for psychosis, Front. Behav. Neurosci., 8, 382, 10.3389/fnbeh.2014.00382 Wykes, 2008, Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor, Schizophr. Bull., 34, 523, 10.1093/schbul/sbm114